Amsterdam, The Netherlands – thromboDx, the molecular diagnostics company that develops and commercializes blood-based diagnostics through its proprietary platelet-powered technology platform, announces that is has received a prestigious EUROSTARS grant.
Focusing on the development of companion diagnostics for therapy monitoring of lung cancer patients, thromboDx decided to lead a consortium and submit a proposal under the acronym PLATO. In PLATO the consortium aims to develop a non-invasive molecular diagnostic tests based on a patented blood platelet technology to monitor the dynamic mutational status of NSCLC patients for personalized medicine.
The Independent Evaluation Panel for EUROSTARS has reviewed all applications and ranked the PLATO-project at position 42 out of 510 eligible project applications, thereby underlining the quality of the proposal and the partners involved.
Besides thromboDx, academic partners VU University Medical Center in Amsterdam, the Netherlands and UMEA University in UMEA, Sweden play an important role in the consortium.
Dr. Jonas Nilsson, Chief Operational Officer at thromboDx commented: “Receiving such a prestigious grant demonstrates that the potential of our platelet technology is being acknowledged by independent experts in the field. We feel confident that we can now step up in the development and validation of companion diagnostics for therapy monitoring of lung cancer patients, focusing in particular on fusion transcripts, overexpressed transcripts and splice variants. There is a high unmet medical need for non-invasive diagnostics platforms providing biomarkers for the next generation targeted therapeutics for the treatment of cancer. This is another boost to the development of our platelet-based RNA diagnostics technology and will allow us to longitudinally monitor RNA transcripts that are not efficiently captured by other blood-based platforms such as circulating free nucleic acids, microvesicles and circulating tumor cells .”
thromboDx (www.thrombodx.com) is a molecular diagnostics company that develops and commercializes blood-based companion diagnostics through its proprietary platelet-powered technology platform and has its offices in Amsterdam, The Netherlands. The technology platform addresses the need for an easily accessible, minimally invasive source for high quality disease-specific nucleic acids in several markets.